FDA-Approved Drug Library Plus
Cat. No. : | CS-L022P | (3036 compounds) |
---|
New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication. First, the risk of failure is lower. Second, the time frame for drug development can be reduced. Third, less investment is needed. Approved drugs have identified bioactivities, good pharmacokinetic characteristics and safety which are suitable for drug repurposing.
MCE owns a unique collection of 3036 approved compounds which have been completed extensive preclinical and clinical studies and have well-characterized bioactivities, safety and bioavailability properties. MCE FDA-Approved Drug Library Plus, with more powerful screening capability, further complements FDA-Approved Drug Library (HY-L022) by adding some compounds with low solubility or solution stability (Part B) to this library. All those supplementary are supplied in powder form.
Size (Pre-dissolved DMSO or Solid) | Stock | Price |
---|---|---|
30 μL/well (10 mM solution) | In-stock | Get quote |
50 μL/well (10 mM solution) | In-stock | Get quote |
100 μL/well (10 mM solution) | In-stock | Get quote |
250 μL/well (10 mM solution) | In-stock | Get quote |
Data Sheet
Description & Advantages
Composition
Contents
Formulation: | A collection of 3036 marketed drugs supplied as pre-dissolved Solutions or Solid |
---|---|
Container: | 96- or 384-well Plate with Peelable Foil Seal; 96-well Format Sample Storage Tube With Screw Cap and Optional 2D Barcode |
Storage: | -80°C |
Shipping: | Blue ice |
Customize Your Library
You can select:- Specific Compounds
- Quantities
- Plate map
- Concentration
- Format (Solid or DMSO Solution)
Please contact us at sales@chemscene.com